ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Healthcare utilization in cancer patients treated with immune checkpoint inhibitors: a population-based study of all patients and 1-year survivors.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but carry significant costs, posing challenges for patients and healthcare systems. This study aimed to evaluate healthcare utilization using real-world data among cancer patients treated with ICIs, monoclonal antibodies (mAbs), protein kinase inhibitors (PKIs), and chemotherapy (Chemo).
methodsThis study utilized data from the Taiwan Cancer Registry and National Health Insurance Database between January 2019 and December 2020, including 133,786 participants diagnosed with stage III, stage IV, or metastatic cancer. Participants were categorized based on the antineoplastic medications. The outcome variables for healthcare service utilization included the number of outpatient visits, outpatient costs, inpatient days, inpatient costs, and total healthcare costs.
resultsThis study included 2722 ICI users, 22,499 mAb users, 30,067 PKI users, and 78,498 Chemo users. ICI users demonstrated significantly higher overall healthcare utilization compared to the other groups (p < 0.001). Additionally, both cancer- and noncancer-related costs were elevated among ICI users, primarily driven by the management of respiratory, endocrine, and urological disorders. Notably, ICI users had lower inpatient healthcare service utilization than mAb users in the 1-year survivor population (p < 0.001).
conclusionThese findings suggest that although ICI use leads to increased overall healthcare utilization, it is associated with a reduction in inpatient healthcare services. This underscores the need for physicians and policymakers to carefully assess the economic implications of ICIs and develop comprehensive strategies to optimize healthcare resources.
Indexed as
Identifiers
41247533What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.